<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> 1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors are two classes of treatments for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, which enhance the well-known 'incretin effect' of <z:mp ids='MP_0003058'>increased insulin secretion</z:mp> in response to food intake </plain></SENT>
<SENT sid="1" pm="."><plain>This concise review introduces both types of incretin-based therapies and focuses on the extra-pancreatic effect of GLP-1 on body weight </plain></SENT>
<SENT sid="2" pm="."><plain>As well as improving glycaemic control in subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, these treatments have the additional benefits of improving weight management in these patients, with GLP-1 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> causing <z:hpo ids='HP_0001824'>weight loss</z:hpo> and DPP-4 inhibitors being weight neutral </plain></SENT>
</text></document>